Abstract
The NCI imbedded the notion of comprehensive quality control and assurance (CQA) in the design concept for the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. PLCO implemented a comprehensive, adaptable quality assurance and control program to span more than 20 years of data collection, coordinate multiple institutions and committees, and integrate a wide variety of complex protocols. CQA concepts, practices, and procedures traced through all aspects of trial management, governance, and operations of PLCO. The driving force behind CQA in PLCO was scientific and clinical credibility of trial data and findings. CQA as implemented in PLCO was operationally analogous to the concept of Total Quality Management (TQM) described in the management literature. This paper describes CQA actualization in PLCO.
Keywords: Cancer screening, clinical trial, comprehensive quality assurance, total quality management.
Reviews on Recent Clinical Trials
Title:Comprehensive Quality Management (CQM) in the PLCO Trial
Volume: 10 Issue: 3
Author(s): John K. Gohagan, Barbara O’Brien, Marsha A. Hasson, Keith D. Umbel, Beth Bridgeman, Barnett S. Kramer, Douglas Reding, Lisa Gren, Patrick Wright, Thomas Riley and Philip C. Prorok
Affiliation:
Keywords: Cancer screening, clinical trial, comprehensive quality assurance, total quality management.
Abstract: The NCI imbedded the notion of comprehensive quality control and assurance (CQA) in the design concept for the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. PLCO implemented a comprehensive, adaptable quality assurance and control program to span more than 20 years of data collection, coordinate multiple institutions and committees, and integrate a wide variety of complex protocols. CQA concepts, practices, and procedures traced through all aspects of trial management, governance, and operations of PLCO. The driving force behind CQA in PLCO was scientific and clinical credibility of trial data and findings. CQA as implemented in PLCO was operationally analogous to the concept of Total Quality Management (TQM) described in the management literature. This paper describes CQA actualization in PLCO.
Export Options
About this article
Cite this article as:
K. Gohagan John, O’Brien Barbara, A. Hasson Marsha, D. Umbel Keith, Bridgeman Beth, S. Kramer Barnett, Reding Douglas, Gren Lisa, Wright Patrick, Riley Thomas and C. Prorok Philip, Comprehensive Quality Management (CQM) in the PLCO Trial, Reviews on Recent Clinical Trials 2015; 10 (3) . https://dx.doi.org/10.2174/1574887110666150730121113
DOI https://dx.doi.org/10.2174/1574887110666150730121113 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Environmental Chemicals and Breast Cancer Risk – A Structural Chemistry Perspective
Current Medicinal Chemistry The Indolylcoumarin COUFIN Exhibits Potent Activity Against Renal Carcinoma Cells without Affecting Hematopoietic System
Anti-Cancer Agents in Medicinal Chemistry Novel Patented Src Kinase Inhibitor
Current Medicinal Chemistry Role of Flavonoids in the Prevention of Gynecological Cancers: Epidemiological Clues
Current Women`s Health Reviews The Novel VEGF<sub>121</sub>-VEGF<sub>165</sub> Fusion Attenuates Angiogenesis and Drug Resistance via Targeting VEGFR2-HIF-1α-VEGF<sub>165</sub>/Lon Signaling Through PI3K-AKT-mTOR Pathway
Current Cancer Drug Targets Proteomics Approach to Illustrate Drug Action Mechanisms
Current Drug Discovery Technologies Procyanidin B2 3,3″-di-O-gallate Inhibits Endothelial Cells Growth and Motility by Targeting VEGFR2 and Integrin Signaling Pathways
Current Cancer Drug Targets Antibiotics Delay Wound Healing: an Effect Reversed by Co-Administering TLR 7 and 9 Ligands
Current Angiogenesis (Discontinued) Biology of Transforming Growth Factor-β Signaling
Current Pharmaceutical Biotechnology Nitroimidazole Radiopharmaceuticals in Hypoxia: Part II Cytotoxicity and Radiosensitization Applications
Current Radiopharmaceuticals Role of the Renin-Angiotensin-Aldosterone System in the Pathogenesis of Atherosclerosis
Current Pharmaceutical Design Therapeutic Potential of High Mobility Group Box-1 in Ischemic Injury and Tissue Regeneration
Current Vascular Pharmacology CoMFA/CoMSIA and Molecular Docking Studies of Novel Matrix Metalloproteinase- 2 Inhibitors Based on L-tyrosine Scaffold
Letters in Drug Design & Discovery Design, Synthesis and Biological Evaluation of Camptothecin Conjugated with NSAIDs as Novel Dual-actin Antitumor Agents
Letters in Drug Design & Discovery Targeting Drugs to APJ Receptor: The Prospect of Treatment of Hypertension and Other Cardiovascular Diseases
Current Drug Targets Urotensin-II Receptor: A Double Identity Receptor Involved in Vasoconstriction and in the Development of Digestive Tract Cancers and other Tumors
Current Cancer Drug Targets MYC-Mediated Synthetic Lethality for Treating Tumors
Current Cancer Drug Targets Dipeptidyl Peptidase IV Inhibitors: A New Paradigm in Type 2 Diabetes Treatment
Current Drug Targets The Induction and Repair of DNA Interstrand Crosslinks and Implications in Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Synthesis, Biological and Computational Evaluation of Novel 2,3-dihydro-2-aryl-4-(4- isobutylphenyl)-1,5-benzothiazepine Derivatives as Anticancer and Anti-EGFR Tyrosine Kinase Agents
Anti-Cancer Agents in Medicinal Chemistry